1,2-Palmitoyl-3-[15-(4-iodophenyl)pentadecan-3-oyl]-rac-glycerol (MIPAG) is
a new agent for the clinical evaluation of pancreatic lipase activity and
has demonstrated promise in preliminary clinical studies with patients affe
cted with pancreatic insufficiency. Iodine-131-MIPAG was initially prepared
via thallium-iodide displacement. Because of the need for a simple method
which is amendable for the routine clinical use of MIPAC we have investigat
ed the preparation and radioiodination of MIPAG utilizing the tributyltin p
recursor, 1,2-palmitoyl-3-[15-(4-tributylstannylphenyl)pentadecan-3-oyl] (T
BT-MIPAG, 2). Compound 2 was prepared via the condensation of 1,2-palmitoyl
-rac-glycerol with 15-(4-tributylstannylphenyl)pentadecanoic acid (TBT-PPA)
prepared from 4-bromophenylacetylene. Electrophilic radioiodination using
peracetic acid with sodium iodide-125 in ethanol at 80 degrees C for 60 min
afforded I-125-MIPAG in (65.9% +/-11.5%) yield and radiochemical purity of
94% (+/-3.0%) after C-18 Sep-Pak purification (n=6). This improved method
for radioiodination utilizing TBT-MIPAG now provides radioiodinated MIPAG f
or routine clinical evaluation. Published by Elsevier Science Ltd.